Julie Leblanc Solene Hoibian Agathe Boucraut Jean-Philippe Ratone Louis Stoffaes Domitille Dano Delphine Louvel-Perrot Brice Chanez Anne-Sophie Chretien Anne Madroszyk Philippe Rochigneux
10.3389/fimmu.2021.799666
Front Immunol
2021 Dec 17;12:799666.
case report celiac disease digestive toxicity immune checkpoint inhibitors immune toxicity nivolumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/34975913/
Celiac Disease / chemically induced Immune Checkpoint Inhibitors / adverse effects Mesothelioma / drug therapy Nivolumab / adverse effects Pleural Neoplasms / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors
Celiac Disease / chemically induced Immune Checkpoint Inhibitors / adverse effects Mesothelioma / drug therapy Nivolumab / adverse effects Pleural Neoplasms / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Case Reports Research Support, Non-U.S. Gov't Aged Autoantibodies / blood Celiac Disease / diagnosis Celiac Disease / immunology Celiac Disease / therapy Diet, Gluten-Free Glucocorticoids / therapeutic use Humans Immunoglobulin A / blood Male Mesothelioma / immunology Pleural Neoplasms / immunology Programmed Cell Death 1 Receptor / immunology Protein Glutamine gamma Glutamyltransferase 2 / immunology Proton Pump Inhibitors / therapeutic use Treatment Outcome Autoantibodies Glucocorticoids Immune Checkpoint Inhibitors Immunoglobulin A PDCD1 protein, human Programmed Cell Death 1 Receptor Proton Pump Inhibitors TGM2 protein, human Nivolumab Protein Glutamine gamma Glutamyltransferase 2
PMC8718638
34975913
Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report
2021